Sanofi-aventis Initiates Research Collaboration in China in the Cancer Stem-Cell Field
PARIS, France - September 14, 2007 - Sanofi-aventis announced today that it has signed a collaboration agreement with the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China, recommended by the Central Chinese Authorities, in order to capitalize on the increasing evidence of the role of cancerstem cells.
The purpose of this agreement is the isolation of acute myeloid leukemia stem cells and the generation of monoclonal antibodies against these cells. Such antibodies would serve as valuable vectors to study these rare cells and may become the basis for new therapeutic strategies.
During a signing ceremony held in Beijing, China, Dr. Qi-Min Zhan, Vice President Research, Chinese Academy of Medical Sciences declared: â€œThis collaboration with a large and well-known pharmaceutical company is a significant progress for the academy; it clearly demonstrates that the work of our scientists on the leading-edge of cancer research is acknowledged. We actively encourage many more such initiativesâ€.
The Institute of Hematology and Blood Diseases Hospital, Tianjin, China is one of the largest of its kind in China and has been treating patients with blood diseases for many decades.
Sanofi-aventis has implemented a significant presence in China and is conducting many clinical trials in this country.
About Chinese Academy of Medical Sciences and Peking Union Medical College The Chinese Academy of Medical Sciences (CAMS) was initially founded in 1906 as the Peking Union Medical College (PUMC), which was the joint project from the then-Chinese government and several British and American religious groups (thus the term "Union"). In 1917, it was re-organized with the support of the Rockefeller Foundation. In 1956, PUMC was affiliated with the Chinese Academy of Medical Sciences (CAMS), which had been established in that year.
Today, CAMS is a prestigious comprehensive academy of medical sciences combining clinical practice and medical education in China. Numerous first-class medical scientists, medical educators and scientific research personnel are on the Academy staff. Currently, there are 18 institutes, 5 branch institutes, 7 affiliated hospitals and 5 colleges in the CAMS.
The Institute of Hematology and Blood Diseases Hospital in Tianjin is one of the institutions affiliated to the CAMS.
Sanofi-aventis is one of the worldâ€™s leading pharmaceutical companies, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts.
These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words â€œexpects,â€ â€œanticipates,â€ â€œbelieves,â€ â€œintends,â€ â€œestimates,â€ â€œplansâ€ and similar expressions. Although sanofi-aventisâ€™ management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under â€œRisk Factorsâ€ and â€œCautionary Statement Regarding Forward-Looking Statementsâ€ in sanofi-aventisâ€™ annual report on Form 20-F for the year ended December 31, 2006. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.